These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394 [TBL] [Abstract][Full Text] [Related]
3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293 [TBL] [Abstract][Full Text] [Related]
5. Review of progressive multifocal leukoencephalopathy and natalizumab. Aksamit AJ Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725 [TBL] [Abstract][Full Text] [Related]
6. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729 [TBL] [Abstract][Full Text] [Related]
7. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369 [TBL] [Abstract][Full Text] [Related]
8. Advances in the management of PML: focus on natalizumab. Fox R Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933 [TBL] [Abstract][Full Text] [Related]
9. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009 [TBL] [Abstract][Full Text] [Related]
10. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Hunt D; Giovannoni G Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169 [TBL] [Abstract][Full Text] [Related]
11. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Rossi F; Newsome SD; Viscidi R Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260 [TBL] [Abstract][Full Text] [Related]
12. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Cutter GR; Stüve O Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045 [TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence. Bacchetta F; Mathias A; Schluep M; Du Pasquier R Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319 [TBL] [Abstract][Full Text] [Related]
14. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. Carruthers RL; Chitnis T; Healy BC Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572 [TBL] [Abstract][Full Text] [Related]
15. The link between VLA-4 and JC virus reactivation. Monaco MC; Major EO Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341 [TBL] [Abstract][Full Text] [Related]